Roots Analysis has done a detailed
study on China
Biopharmaceutical Contract Manufacturing Market, 2020-2030, covering key
aspects of the industry’s evolution and identifying potential future growth
opportunities.
To order this 250+
page report, which features 100+ figures and 120+ tables, please visit this link
Key Market Insights
§ Over 35 CMOs / CDMOs
in China claim to offer a variety of services related to development and manufacturing
of a wide range of biotherapeutic products
§ Several players
provide one-stop solutions and are capable of operating at various scales; the
landscape includes a mix of both established players and new entrants
§ In order to cater to
the evolving needs of clients / sponsors, CMOs have established facilities
across different regions of China; Eastern China, with the maximum number of
sites, has emerged as a manufacturing hub
§ With over 80 deals
inked in past five years, there has been a surge in the partnership activity
within this domain; majority of these collaborations were signed for the
development and manufacturing of antibody-based products
§ Big pharma players have also made significant investments in this
region, including establishing new facilities, expanding existing R&D
centers and growing manufacturing facilities, focused on biotherapeutics
§ We expect global
biopharmaceutical developers to continue to outsource their manufacturing
operations to China in the long term; we anticipate the CMO industry in the
region to grow at an annualized rate of ~13%, till 2030
For more information, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Chapter Overview
1.2.
3.3. Manufacturing
of Biopharmaceuticals
3.3.1. Types of
Expression Systems Used
3.3.1.1. Bacterial
Expression Systems
3.3.1.2. Yeast
Expression Systems
3.3.1.3. Insect
Expression Systems
3.3.1.4. Plant
Expression Systems
3.3.1.5. Mammalian
Expression Systems
3.3.1.6. Fungal
Expression Systems
3.3.2. Processing
Steps
3.3.2.1. Upstream
Processing
3.3.2.2. Downstream
Processing
3.4. Overview of
Contract Manufacturing
3.4.1. Contract
Manufacturing Scenario in China
3.5. Need for
Outsourcing in the Biopharmaceutical Industry
3.5.1. Biopharmaceutical
Outsourcing in China: Regulatory Scenario
3.6. Commonly
Outsourced Operations in the Biopharmaceutical Industry
3.7. Basic
Guidelines for Selecting a CMO Partner
3.8. Advantages
of Outsourcing Manufacturing Services
3.8.1. Benefits of
Engaging Chinese Contract Service Providers
3.9. Risks and
Challenges Associated with Biopharmaceutical Contract Manufacturing
3.9.1. Challenges Associated
with Engaging Chinese Contract Service Providers
3.10. Future
Perspective
4. CASE STUDY:
COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter
Overview
4.2. Small
Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison
of Key Characteristics
4.2.2. Comparison
of Manufacturing Processes
4.2.3. Comparison
of Key Manufacturing-Related Challenges
5. COMPETITIVE
LANDSCAPE
5.1. Chapter
Overview
5.2. Chinese
Biopharmaceutical Contract Manufacturers: Overall Market Landscape
5.2.1. Analysis by
Year of Establishment
5.2.2. Analysis by
Company Size
5.2.3. Analysis by
Scale of Operation
5.2.4. Analysis by
Location of Headquarters
5.2.5. Analysis by
Location of Manufacturing Facilities
5.2.6. Analysis by
Type of Product
5.2.7. Analysis by
Types of Services Offered
5.2.8. Analysis by
Type of Biologic
5.2.9. Analysis by
Expression System Used
5.2.10. Analysis by
Type of Bioreactor Used
5.2.11. Analysis by
Mode of Operation of Bioreactor
5.2.12. Analysis by
Packaging Form Used
5.2.13. Analysis by
Regulatory Accreditations / Certifications
6. COMPANY
PROFILES
6.1 Chapter
Overview
6.2 ChemPartner
Biologics
6.2.1. Company
Overview
6.2.2. Service
Portfolio
6.2.3. Manufacturing
Facilities and Capabilities
6.2.4. Recent
Developments and Future Outlook
6.3. JHL Biotech
6.3.1. Company
Overview
6.3.2. Service
Portfolio
6.3.3. Manufacturing
Facilities and Capabilities
6.3.4. Recent
Developments and Future Outlook
6.4. JOINN
Biologics
6.4.1. Company
Overview
6.4.2. Service
Portfolio
6.4.3. Manufacturing
Facilities and Capabilities
6.4.4. Recent
Developments and Future Outlook
6.5 MabPlex
6.5.1. Company
Overview
6.5.2. Service
Portfolio
6.5.3. Manufacturing
Facilities and Capabilities
6.5.4. Recent
Developments and Future Outlook
6.6. Mycenax
Biotech
6.6.1. Company
Overview
6.6.2. Service
Portfolio
6.6.3. Manufacturing
Facilities and Capabilities
6.6.4. Recent
Developments and Future Outlook
6.7. WuXi AppTec
6.7.1. Company
Overview
6.7.2. Financial Information
6.7.3. Service
Portfolio
6.7.4. Manufacturing
Facilities and Capabilities
6.7.5. Recent
Developments and Future Outlook
7. PARTNERSHIPS
7.1 Chapter
Overview
7.2. Partnership
Models
7.3. Chinese
Biopharmaceutical Contract Manufacturers: Recent Partnerships
7.3.1. Analysis by
Year of Partnership
7.3.2. Analysis by Type
of Partnership
7.3.3. Analysis by
Scale of Operation
7.3.4. Analysis by
Type of Biologic
7.3.5. Analysis by
Focus Area
7.3.6. Analysis by
Therapeutic Area
7.3.7. Most Active
Players: Analysis by Number of Partnerships
7.3.8. Geographical
Analysis
7.3.9. Geographical
Distribution by Number of Partnerships
7.3.10. Intercontinental
and Intracontinental Agreements
8. RECENT
EXPANSIONS
8.1. Chapter
Overview
8.2. Chinese
Biopharmaceutical Contract Manufacturers: Recent Expansions
8.2.1. Analysis by
Year of Expansion
8.2.2. Analysis by
Type of Expansion
8.2.3. Analysis by
Scale of Operation
8.2.4. Analysis by
Type of Biologic
8.2.5. Analysis by
Location of Expansion Project
8.2.6. Analysis by
Capacity of Expanded Facility
8.2.7. Most Active
Players: Analysis by Number of Expansions
8.2.8. Analysis by
Region
9. CLINICAL
TRIAL ANALYSIS
9.1. Chapter
Overview
9.2. Scope and
Methodology
9.3 Clinical
Trial Analysis: Biologic Drugs
9.3.1. Analysis by
Trial Registration Year
9.3.2. Analysis by
Trial Phase
9.3.3. Analysis by
Trial Status
9.3.4. Geographical
Analysis by Number of Clinical Trials
9.3.5. Geographical
Analysis by Enrolled Patient Population
9.3.6. Analysis of
Enrolled Patient Population by Trial Registration Year
9.3.7. Analysis of
Enrolled Patient Population by Trial Phase
9.3.8. Analysis by
Type of Sponsor / Collaborator
9.3.9. Most Active
Players: Analysis by Number of Registered Trials
9.3.10. Analysis by
Clinical Trial Center
10. REGIONAL
CAPABILITY ANALYSIS
10.1. Chapter
Overview
10.2. Assumptions
and Key Parameters
10.3. Overall
Landscape of Chinese Biopharmaceutical Contract Manufacturers
10.4. Regional
Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern
China
10.5. Regional
Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China
10.6. Regional
Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China
10.7. Regional
Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern
China
11. CAPACITY
ANALYSIS
11.1. Chapter
Overview
11.2. Assumptions
and Methodology
11.3. Chinese
Biopharmaceutical Contract Manufactures: Installed Capacity
11.3.1. Analysis by
Company Size
11.3.2. Analysis by
Scale of Operation
11.3.3. Analysis by
Expression System Used
11.3.4. Analysis by
Location of Manufacturing Facility
11.3.5. Analysis by Company
Size and Location of Manufacturing Facility
11.3.6. Analysis by Company
Size and Location of Manufacturing Facility
11.4. Concluding
Remarks
12. BIG PHARMA BIOPHARMACEUTICAL
MANUFACTURING INITIATIVES IN CHINA
12.1. Chapter
Overview
12.2. List of
Biopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Players
in China
12.2.1. Analysis by
Number of Initiatives
12.2.2. Analysis by
Year of Initiative
12.2.3. Analysis by Company
and Year of Initiative
12.2.4. Analysis by
Type of Initiative
12.2.5. Analysis by Type
of Biologic
12.3. Competitive
Benchmarking of Big Pharmaceutical Players
12.3.1. Harvey Ball
Analysis: Big Pharma Investment Summary
12.3.2. Geographical
Analysis by Investment Made
13. MAKE VERSUS
BUY DECISION MAKING FRAMEWORK
13.1. Chapter
Overview
13.2. Assumptions
and Key Parameters
13.3. Chines
Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.4. Conclusion
14. MARKET
SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter
Overview
14.2. Key
Assumptions and Forecast Methodology
14.3. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030
14.3.1. Biopharmaceutical
Contract Manufacturing Market in China for APIs, 2020-2030
14.3.2. Biopharmaceutical
Contract Manufacturing Market in China for FDFs, 2020-2030
14.4. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Distribution by Expression
System Used
14.4.1. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Mammalian Systems
14.4.2. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Microbial Systems
14.4.3. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Other Expression
Systems
14.5. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Distribution by Scale of
Operation
14.5.1. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Preclinical /
Clinical Scale Operations
14.5.2. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Commercial
Operations
14.6. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Distribution by Size of
Manufacturers
14.6.1. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Small Companies
14.6.2. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Mid-sized Companies
14.6.3. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Large and Very
Large Companies
14.7. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Distribution by Type of
Biologic
14.7.1. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Antibodies
14.7.2. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Vaccines
14.7.3. Biopharmaceutical
Contract Manufacturing Market in China, 2020-2030: Share of Other Biologics
15. COVID-19
Impact on China Biopharmaceutical CMO Market
15.1. Chapter
Overview
15.2. Evaluation
of Impact of COVID-19 Outbreak
15.2.1. Initiatives and Opinions of Key Players
15.2.1.1. WuXi AppTec
15.2.1.2. Boehringer Ingelheim
15.2.1.3. GE Healthcare
15.2.1.4. Lonza
15.2.1.5. AmbioPharm
15.2.2. Impact of
China Biopharmaceutical Contract Manufacturing Market
15.3. Key
Strategies to Adopt: A Bird’s Eye View
15.3.1. Immediate
Steps
15.3.2. Short /
Long-Term Steps
16. SWOT
ANALYSIS
16.1. Chapter
Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison
of SWOT Factors
16.7. Concluding
Remarks
17. FUTURE OF
THE CHINA BIOPHARMACEUTICAL CMO MARKET
17.1. Chapter
Overview
17.2. Outsourcing
Activities Anticipated to Increase in Future
17.3. Shift from
One-time Contracts to Strategic Partnerships
17.4. Adoption of
Innovative Technologies
17.4.1. Single Use Bioreactors
17.4.2. Novel Bioprocessing Techniques
17.4.3. Bioprocess Automation
17.5. Growing Popularity
of the Quality by Design Principle in Bioprocessing
17.6. Increasing
Focus on Niche Therapeutic Areas
17.7. Biosimilars
Market to Contribute to Contract Service Revenues
17.8. Capability
and Facility Expansions to Establish One Stop Shop Expertise
17.9. Increase in
Financial In-flow and Outsourcing Budgets
17.10. Challenges
Faced by Sponsors and Service Providers
17.10.1. Concerns Associated with Single Use Systems
17.10.2. Issues Related to Capacity Fluctuations
17.11. Concluding
Remarks
18. INTERVIEW /
SURVEY TRANSCRIPT(S)
19. APPENDIX 1:
TABULATED DATA
20. APPENDIX 2:
LIST OF COMPANIES AND ORGANISTIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
